Aamer Qureshi, MD
Interventional Cardiology · Charlotte, NCNPI 1043266943
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,152 of the $26,552 with a category attached, or 79.7%. It is spread thinly across 46 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $7,217 and has fallen 61.8% since, to $2,761 in 2025.
Across 995 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$5K
- Johnson & Johnson$2K
- Novartis$2K
- Bayer$2K
- Cook Medical LLC$2K
- Amgen$1K
- plus $12K from 40 others
Across 30 payments — averaging $3836.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$25K
- Bayer$24K
- E.r. Squibb & Sons, L.L.C.$24K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19K
- Novartis$14K
- Vifor (international) Ltd.$9K
What the payments were for
- Consulting fees$4002%
- Speaking & faculty fees$3,41513%
- Travel & lodging$1,5176%
- Food & beverage$21,15280%
- Education$680%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Peripheral$777
- Zilver PTX$462
- Adempas$400
- PRALUENT$338
- Cook Medical Zilver PTX$337
- VERQUVO$328
- FFRct$259
- FUROSCIX$255
- XARELTO$249
- BRILINTA$239
- Repatha$231
- NEXLIZET$228
- NEXLETOL$228
- Cook Medical Peripheral Intervention$191
- Cook$175
- XEOMIN$150
- ELIQUIS$125
- Kerendia$122
- EVKEEZA$121
- AURORA EV-ICD MRI SURESCAN$100
How this compares
$26,552 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 12 | $281,389 |
| OpsumitMacitentan | 21 | $266,490 |
| EliquisApixaban | 264 | $238,296 |
| AdempasRiociguat | 14 | $184,198 |
| XareltoRivaroxaban | 177 | $167,672 |
| EntrestoSacubitril/Valsartan | 126 | $124,548 |
| JardianceEmpagliflozin | 116 | $117,015 |
| MultaqDronedarone Hcl | 33 | $62,272 |
| FarxigaDapagliflozin Propanediol | 44 | $42,719 |
| Ambrisentan | 15 | $37,183 |
| BrilintaTicagrelor | 37 | $19,491 |
| VerquvoVericiguat | 11 | $19,006 |
| Repatha SureclickEvolocumab | 17 | $14,522 |
| LivaloPitavastatin Calcium | 18 | $11,450 |
| CorlanorIvabradine Hcl | 14 | $11,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,091 | $547,87933 claims |
| PfizerEliquis | $357 | $238,296264 claims |
| BayerAdempas | $2,066 | $184,19814 claims |
| Johnson & JohnsonXarelto | $2,373 | $167,672177 claims |
| NovartisEntresto | $2,137 | $124,548126 claims |
| Boehringer IngelheimJardiance | $721 | $117,015116 claims |
| Sanofi-aventis U.S. LLCMultaq | $4,675 | $62,27233 claims |
| AstraZenecaFarxiga, Brilinta | $973 | $62,21081 claims |
| MerckVerquvo | $877 | $19,00611 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $722 | $11,45018 claims |
| AmgenCorlanor | $1,298 | $11,33514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Charlotte
- Oluseun AlliCharlotte$485K
- Glen FandettiCharlotte$46K
- John PasquiniCharlotte$32K
- Daniel PuCharlotte$23K
- Nyal BorgesCharlotte$18K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.